CRISPR Therapeutics Aktie
| 53,07USD | 4,14USD | 8,46% |
WKN DE: A2AT0Z / ISIN: CH0334081137
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 473 | 458 | 407 | 393 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,93 | 0,00 | 0,91 | 0,09 | 0,00 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2 418 | 1 853 | 1 908 | 1 937 | 1 986 |
| Summe Anlagevermögen | 334 | 390 | 321 | 305 | 280 |
| Summe Aktiva | 2 752 | 2 243 | 2 230 | 2 242 | 2 265 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 352 | 368 | 347 | 310 | 343 |
| Summe Eigenkapital | 2 399 | 1 875 | 1 883 | 1 932 | 1 922 |
| Summe Passiva | 2 752 | 2 243 | 2 230 | 2 242 | 2 265 |
Adresse
| Baarerstrasse 14, 6300 Zug | |
| Telefon | +41 (41) 561-32-77 |
| Internet | http://www.crisprtx.com |
Management
|
Ali Behbahani
Independent Director |
|
Briggs W. Morrison
Director |
|
Christian Rommel
Independent Director |
|
Douglas A. Treco
Lead Independent Director |
|
Harold Edward Fleming
Independent Director |
|
James R. Kasinger
Secretary & General Counsel |
|
John T. Greene
Independent Director |
|
Katherine A. High
Independent Director |
|
Maria Fardis
Independent Director |
|
Megan Wherry Menner
Head-Human Resources |
|
Naimish Patel
Chief Medical Officer |
|
Raju Prasad
Chief Financial & Accounting Officer |
|
Samarth Kulkarni
Chairman & Chief Executive Officer |
|
Sandesh Mahatme
Independent Director |
|
Simeon J. George
Independent Non-Executive Director |
|
Stephen R. Kennedy
Head-Technical Operations |
|
Susan Kim
Head-Investor Relations Contact |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.